PharmRev articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Jump to section
- Article
- Abstract
- I. Introduction
- II. Incretin Mimetics and Incretin Analogs
- III. Dipeptidyl-Peptidase 4 Inhibitors
- IV. Sodium-Coupled Glucose Cotransporter 2 Inhibitors
- V. Pramlintide (Amyloid Deposits, Amylin)
- VI. Peroxisome Proliferator-Activated Receptor Agonists (New Glitazones and Glitazars); Glitazars Are Dual Peroxisome Proliferator-Activated Receptor Agonists
- VII. New Glinides
- VIII. Enzymes as Targets (Signaling Systems)
- IX. Physiological Compounds (Hormones)
- X. New Remedies with Respect to Late Complications of Diabetes
- XI. G-Protein-Coupled Receptors
- XII. Hypothetical New Targets (Emerging Targets) Still Lacking Therapeutic Significance
- Acknowledgments
- Authorship Contributions
- Footnotes
- References
- Figures & Data
- Info & Metrics
- eLetters
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement